UCONN | SCHOOL OF DENTAL MEDICINE

ORAL AND FACIAL PAIN MANAGEMENT TOOLKIT

Table of Contents

Workflow: Acute Oral, Facial and Postoperative Pain Management in Adult Patients	4
Opioid Alternatives	5
Comparison Chart: NSAIDS & Other Analgesics	5
Non-Medication Alternatives to Care for Pain	ε
Patient Handout: Managing Pain After Dental Care	7
Screening Tools	8
SBIRT Pre-Screening Form	8
Opioid Risk Tool (ORT)	9
Voluntary NonOpioid Directive (VNOD)	10
Voluntary NonOpioid Directive Form	10
Patient Guide: Opioid Opt-Out Form	11
Opioid Prescribing Tools	12
CPMRS Checklist	12
Morphine Milligram Equivalent (MME)	13
Pain Medication Agreement (PMA)	14
Patient Handout: Medications to Avoid While on Opioids	15
Relevant Literature for Dental Providers	16
New Persistent Opioid Use – Dental One Page Infographic	16
4 Reasons Why (Dental)	17
Community Referrals and Resources for Substance Use Disorder	18
Board Certified Specialists of Orofacial Pain and TMD in Connecticut	18
Orofacial Pain Consult Request Template	19
CT State Legislation Related to Opioid Prescribing	20
Opioid Related Guidelines and Recommendations Relevant to Dentists	2 1
Appendices	22
Appendix I: Voluntary NonOpioid Directive Fact Sheet	23
Appendix II: Opioid Onset of Action	24
Appendix III: Morphine Milligram Equivalent (MME) Conversion Factors	25
Appendix IV: CPMRS Registration Policy and Procedures Manual	26
Appendix V: Ohio State Board of Pharmacy. Media Release: Dentist Enters Plea for Misuse of Ohio Prescription Monitoring System; October 8, 2013	27



Table of Figures

Figure 1. Acute, Oral, Facial and Postoperative Pain Management in Adult Patients: Recommended Workflow	4
Fable 1. Community Referrals and Resources for Substance Use Disorder in Connecticut	18
Table 2. Board Certified Specialists of Orofacial Pain and TMD in Connecticut	18
Table 3. CT State Legislation Related to Opioid Prescribing	20
Table 4. Opioid Related Guidelines and Recommendations Relevant to Dentists	21



Recommended Workflow: Acute Oral, Facial and Postoperative Pain Management in Adult Patients

Check for Consider long-acting Determine if Consider NSAID & APAP & NSAID local anesthetics patient has VNOD APAP combination contraindication **Unresolved** Clarify findings Screen for risk Yes Low Mod - High Check CPMRS for with patient or of substance Inform patient of Reevaluate need red flag health care red flags misuse screening result for opioids (ex. ORT) provider red flags Confirm: ■ No opioid If alternative Obtain consent for opioid contraindication or drug Resolved interactions therapy & document in EHR No past & family history of SUD APAP: Acetaminophen Prescribe lowest potency for **CPMRS:** Connecticut Prescription short acting opioid for Monitoring & Reporting System no longer than 3 days EHR: Electronic Health Record NSAID: Non-steroidal anti-inflammatory drugs Document prescription & **ORT**: Opioid Risk Tool patient instructions for analgesia in EHR SUD: Substance Use Disorder UCONN | SCHOOL OF VNOD: Voluntary NonOpioid Directive DENTAL MEDICINE

Figure 1. Acute, Oral, Facial and Postoperative Pain Management in Adult Patients: Recommended Workflow

Opioid Alternatives

Class / Agent

Comparison Chart: NSAIDS & Other Analgesics

ORUDIS®

NAPROSYN®

DAYPRO[®]

SURGAM®

FELDENE®

MOBIFLEX[®]

RELAFEN®

 $IDARAC^{^{\circledR}}$

 $VIOXX^{\mathbb{R}}$

TYLENOL®

CELEBREX[®] ◆

Ketoprofen

Oxaprozin

Piroxicam

Tenoxicam

Nabumetone

Floctafenine

Celecoxib

Rofecoxib

Oxicams

Naproxen ###

Tiaprofenic Acid

Naphthylalkanones

Anthranilic Acids

Mefenamic Acid

Acetaminophen

Piroxicam-beta-cyclodextrin BREXIDOL®

Comparison Chart: NSAIDS & Other Analgesics

Salicylates OTC; 650mg supp; 80,325mg ASPIRIN® **ASA-Plain** 325-650mg q4-6h tab; 81,325,650,975mg EC tab; 4g 325-975mg QID **ASA-Enteric Coated** ENTROPHEN® 650mg po QID \$11 irreversible platelet inhibition DOLOBID[®] 250-500mg BID 1.5g 250mg po BID \$37 250,500mg tab Diflunisal Non-acetylated Salicylates - less adverse GI reactions, less cross-allergy in NSAID (& CSI?) allergic patients; available, but not commonly used DISALCID[®] 500,750mg tab 1000mg TID $1500 \mathrm{mg}$ po BID \$54 Salsalate Choline Mg Trisalicylate TRILISATE® 1-1.5g BID \$36 500mg tab 1000mg po BID Indole Acetic Acids Indomethacin INDOCID[®] 25-50mg TID 25,50mg cap; 50,100mg supp 200mg 25mg po TID \$17 CLINORIL 150,200mg tab; PD 150-200mg BID 400mg 150mg po BID \$34 Sulindac 200-600mg TID-QID Tolmetin TOLECTIN® 200,600mg tab; 400mg cap 2g 400mg po TID \$53 Phenylacetic Acids 25,50mg EC tab; 50,100mg Diclofenac ### 200mg VOLTAREN® 25-50mg BID-TID 50mg po TID \$22 supp; 75,100mg SR tab 1 tab BID-TID \$47 Diclofenac+Misoprostol ARTHROTEC-50® $(50mg + 200\mu g)$ tab 200mg/ One tab po BID $(75mg + 200\mu g)$ tab ARTHROTEC-75 1 tab OD-BID 800µg One tab po BID \$61 Pyrolizine Carboxylic Acids 10mg po q6h x7d max 10-30mg **IM** q4-6h ##; 10mg tab; 30mg injectable IM formulation available 40mg \$67 ## TORADOL[®] ★ Ketorolac 10mg po QID ## 120mg Pyranocarboxylic Acids ULTRADOL[®] **⋄** Etodolac ~COX-2 selective; 200,300mg cap 200-600mg BID 1.2g 300mg po BID \$50 Propionic Acids Fenoprofen NALFON® 300mg cap; 600mg tab 300-600mg TID-QID 3.2g 600mg po TID \$63 ANSAID® 50, 100mg tab Flurbiprofen 50-100mg TID-QID 300mg 100mg po BID \$32 OTC: 200mg tab; 100mg/5ml MOTRIN® 200-800mg TID-QID 400mg po QID \$13 **Ibuprofen** 3.2g susp.; Rx. 300,400,600mg tab

50,100mg EC; 200mg SR tab

125mg/5ml susp; 500mg supp;

20mg tab (may give 40mg x1 initially)

~COX-2 selective; PD; 500mg tab

250mg cap; (initially 500mg x1)

12.5, 25mg tab; 12.5mg/ml

Analgesics: Non-Anti-inflammatory - least GI risk; recommended as first-choice option in osteoarthritis; monitor LFTs in chronic use OTC; 325,500mg tab; 120,

susp; methotrexate DI

(EC available non-formulary) 600mg caplet; long t1/2 (50h)

200,300mg tab

20mg tab

200,400mg tab

100,200mg cap

10,20mg cap & supp

- long t1/2 (>50h)

- long t1/2

50mg cap; 50,100mg supp 125,250,375,500mg; 750mg SR;

Comments / **Products**

Prepared by: Loren Regier, Sharon Downey - The RxFiles,

Usual Dosage

Range

25-100mg TID-QID

125-500mg BID

600-1800mg OD

200-300mg BID

10-20mg OD

20mg OD x 7d max

20-40mg OD

1-2g OD

200-400mg TID-QID

250mg QID x 7d max

200mg BID (RA;\$97)

12.5-25mg OD (OA)

100mg BID (OA) -

300mg

1.5g

1.8g

600mg

20mg

40mg

2g

1.2g

400mg

50mg po TID

375mg po BID

600mg po OD

200mg po BID

20mg po OD

20mg po OD ###

20mg po OD

1g po OD

200mg po QID

250mg po QID ##

100mg BID

200mg OD

12.5mg OD

25mg OD

650mg po QID

\$25

\$16

\$30

\$32

\$33

\$97 ^{##}

\$51

\$43

\$59 \$37 ##

\$52

\$52

\$12

AUG/2000

Cost x30 days #

(comparative dose)

Max

/day

if for acute pain: 50mg X1, then 25-50mg od (X 5d)

COX-2 Specific Inhibitors (CSIs) - similar efficacy to NSAIDs but less GI upset/ulceration & no effect on platelets; lack long-term/published data

³²⁵⁻¹⁰⁰⁰mg TID-QID 325,650mg supp; syrup/elixir # Approximate retail cost to consumer based on applicable acquisition cost, markup, and dispensing fee. Lowest generic price used where available.

Cost comparison based on lowest anti-inflammatory dose (as per Micromedex). Lower doses of NSAIDs often effective for analgesia (except CSIs).

Monthly cost for ketorolac, mefenamic acid, & Brexidol® shown for comparison only; Recommended maximum length of oral treatment is 7 days.

Fast-acting formulations available but non-formulary in SK (Anaprox® 275, 550mg tabs; Voltaren Rapide® 50mg tabs); slightly faster onset, but more expensive.

Non-Medication Alternatives to Care for Pain

TYPICALLY COVERED BY INSURANCE

Physical therapy

Occupational therapy

Mental health treatment

Chiropractic therapy

Nerve stimulation

Injections

Specialist pain care

Surgery

Pain classes

SOMETIMES COVERED BY INSURANCE

Acupuncture

Massage

Reiki

TYPICALLY NOT COVERED BY INSURANCE

Heat and cold therapy (heating pads, ice

packs)

Attention to proper sleep

Stretching

Exercise

Weight loss

Relaxation or stress reduction training

Music therapy

Self-care techniques

Counseling and coaching

Meditation

Rehabilitation

Support Group

Patient Handout: Managing Pain After Dental Care

Available for download and customization with your organization's logo at: https://michigan-open.org/patient-community-education/



DISCUSS WITH YOUR DENTIST:

- ALL medications you are taking, including:
- ► Antidepressants (like Prozac® or Celexa®)
- ► Opioids (like Vicodin® or Norco®)
- ► Sedatives (like Ambien® or Seroquel®)
- Benzodiazepines (like Valium, Xanax, or Klonopin*)
- ▶ Other prescription pain medications
- ▶ Illegal Drugs
- If you can use over-the-counter medications, acetaminophen (Tylenol[®]) ibuprofen (Motrin[®] or Advil[®]) to manage your pain.
- · What you should do if your pain is not controlled.

UNDERSTANDING PAIN AFTER A PROCEDURE

THINGS TO KNOW:

- Dental pain is mostly caused by tissue inflammation (swelling) from the procedure or the dental issue.
- This is called acute pain. Acute pain does not last a long time.
- This acute, dental pain is normal and is usually worst the first 1-3 days.
- Your pain should be well controlled with a schedule of over-the-counter acetaminophen (Tylenol) and ibuprofen (Motrin or Advil)

If you have severe pain that is not managed by the **regular use** of <u>both</u> acetaminophen and ibuprofen, please call your dentist.

MANAGING PAIN

For the First 3 Days

After your procedure, use acetaminophen and ibuprofen **together** at *regular*, *scheduled* times:

9 AM	Acetaminophen & Ibuprofen	1000 mg (2 pills of 500 mg) 600 mg (3 pills of 200 mg)
3 PM	Acetaminophen & Ibuprofen	1000 mg (2 pills of 500 mg) 600 mg (3 pills of 200 mg)
9 PM	Acetaminophen & Ibuprofen	1000 mg (2 pills of 500 mg) 600 mg (3 pills of 200 mg)

After 3 days

Only take medications if you have pain.

Medication is only **one** part of your pain management plan. Continue using **non-drug options** to help manage pain:

NON-DRUG OPTIONS

Ice



Meditation of dental work



Massage area of dental work

Soft food diet

Relaxation:





Listen to music

Screening Tools

SBIRT Pre-Screening Form

SBIRT guides clinicians to provide brief, early intervention and referrals to treatment for individuals identified as "at-risk" of, or currently suffering from, substance use disorders.

It is recommended that the pre-screening form be administered to all adult patients prior to considering prescribing of opioids for pain. It rules out patients who are at low or no-risk using one pre-screening question for alcohol and one pre-screening question for drugs.

Available for download at: https://www.sbirt.care/pdfs/tools/Pre-Screen-Annual%20Screen.PDF

Once a year, all our patients are asked to complete this form because drug and alcohol use can affect your health as well as medications you may take. Please help us provide you with the best medical care by answering the questions below.		
Are you currently in recovery for alcohol or substance use?	es 🗌 No	
Alcohol: One drink = 12 oz. beer 5 oz. wine		1.5 oz. liquor (one shot)
	None	1 or more
MEN: How many times in the past year have you had 5 or more drinks in a day?	0	0
WOMEN: How many times in the past year have you had 4 or more drinks in a day?	0	0
Drugs: Recreational drugs include methamphetamines (speed, crystal), car inhalants (paint thinner, aerosol, glue), tranquilizers (Valium), bard hallucinogens (LSD, mushrooms), or narcotics (heroin).	None	1 or more
inhalants (paint thinner, aerosol, glue), tranquilizers (Valium), barb		1 or more

Opioid Risk Tool (ORT)

The ORT is a questionnaire developed by Lynn R. Webster, MD to screen patients for risk of opioid misuse. The ORT is designed to help practitioners with clinical decision-making.

Available for download at: https://www.drugabuse.gov/sites/default/files/opioidrisktool.pdf

Online ORT calculator available at: https://www.mdcalc.com/opioid-risk-tool-ort-narcotic-abuse

This tool should be administered to patients upon an initial visit prior to beginning opioid therapy for pain management. A score of 3 or lower indicates low risk for future opioid abuse, a score of 4 to 7 indicates moderate risk for opioid abuse, and a score of 8 or higher indicates a high risk for opioid abuse.

Mark each box that applies	Female	Male	
Family history of substance abuse			
Alcohol	1	3	
Illegal drugs	2	3	
Rx drugs	4	4	
Personal history of substance abuse	•		
Alcohol	3	3	
Illegal drugs	4	4	
Rx drugs	5	5	
Age between 16—45 years	1	1	
History of preadolescent sexual abuse	3	0	
Psychological disease			
ADD, OCD, bipolar, schizophrenia	2	2	
Depression	1	1	
Scoring totals			

Webster LR, Webster R. Predicting aberrant behaviors in Opioid-treated patients: preliminary validation of the Opioid risk tool. Pain Med. 2005; 6(6): 432.


Voluntary NonOpioid Directive (VNOD)

Voluntary NonOpioid Directive Form

A "voluntary nonopioid directive form" (the "Form"), as established under and defined in section 4 of Public Act 17-131, an act Preventing Opioid Diversion and Abuse (the "Act"), available at: https://www.cga.ct.gov/2017/ACT/pa/2017PA-00131-R00HB-07052-PA.htm, enables an individual to voluntarily request that prescribing practitioners not prescribe opioid drugs and not issue a medication order for opioid drugs for such individual. This form is also known as an "opioid opt-out form."

For details about liabilities under the act, see Appendix II


It is recommended that providers make this form available to patients and that an alert is evident a non-opioid directive is chosen. It is recommended that providers include the option of a VNOD in the medical history.



Available for download at: https://business.ct.gov/-/media/DPH/CT-VNOD-Form_FINAL.pdf

Patient Guide: Opioid Opt-Out Form

Download and share this printable patient guide to educate patients about opioid analgesics, their option to opt-out of being prescribed opioids, and questions to ask their provider.






Available for download at: https://health.uconn.edu/pain-center/resources/materials/

Opioid Prescribing Tools

CPMRS Checklist

Download and use this tool as a guide for pain management decision making when checking the CPMRS.






Available for download at: https://portal.ct.gov/-/media/DCP/drug_control/PMP/CHANGE-the-SCRxIPT/prescriber-card_nocrop.pdf


Morphine Milligram Equivalent (MME)

Use this tool to calculate the daily morphine milligram equivalent dose when considering prescribing an opioid to opioid-naïve and opioid tolerant adult patients.



Tip sheet available for download at:

https://www.cdc.gov/drugoverdose/pdf/calculating_total_daily_d ose-a.pdf





Online MME calculator available at: https://www.mdcalc.com/morphine-milligram-equivalents-mme-calculator#use-cases

Pain Medication Agreement (PMA)

Pain Medication Agreements (PMA) are used by medical practitioners for patients beginning long-term treatment with opioid analgesics or other controlled substances. PMAs contain statements to help ensure patients understand their role and responsibilities regarding their treatment e.g. how to obtain refills, conditions of medication use, the conditions under which their treatment may be terminated, and the responsibilities of the health care provider. PMAs aim to facilitate communication between patients and healthcare providers and to resolve any questions or concerns before initiation of long-term treatment with a controlled substance.

We recommend that dental providers ask patients about PMAs in the medical history and that an alert is made evident to providers when a PMA is present.





Sample Pain Medication Agreements available for download at: https://www.mndental.org/files/Sample-Patient-Agreement-Forms.pdf

Patient Handout: Medications to Avoid While on Opioids

This handout can be shared with patients with post-op instructions to encourage further discussion with the dispensing pharmacy.

Please note this list is not comprehensive and any medication changes should be discussed with your doctor or pharmacist prior to taking with your opioid.

Medications to Avoid While on Opioids

- ANY MEDICATION OR SUBSTANCE THAT MAKES YOU FEEL TIRED OR SEDATED
- ALCOHOL

OPIOIDS

Generic	Brand
	Belbuca, Buprenex,
Buprenorphine	Butrans, Probuphine
	Implant, Subutex
Butalbital	
(often combined with	Fioricet, Fiorinal
acetaminophen or aspirin)	a
Butorphanol	Stadol
Codeine	Tylenol #3
	Actiq, Duragesic, Fentora,
Fentanyl	Lazanda, Sublimaze,
	Subsys
	Hydromet, Hysingla,
Hydrocodone	Lortab, Norco, Tussigon, Vicodin, Vicoprofen,
	Zohydro
Hydromorphone	Dilaudid, Exalgo
Levorphanol	Levo-Dromoran
Meperidine	Demerol
Methadone	Dolophine, Methadose
	Avinza, Duramorph,
Morphine	Embeda, Kadian, MS
	Contin, MS-IR,
Nalbuphine	Nubain, Raltrox
	Roxicodone, Endocet,
Oxycodone	Oxaydo, Oxycontin, Oxy-
	IR, Percodan, Percocet,
	Roxicet, Xtampza
Oxymorphone	Opana
Pentazocine	Talwin
Tapentadol	Nucynta
Tramadol	Conzip, Ultram, Ultracet


Non-Opioids

Generic	Brand
Alprazolam	Xanax
Baclofen	Gablofen, Lioresal
Carisoprodol	Soma
Chlorodiazepoxide	Librium
Clonazepam	Klonopin
Cyclobenzaprine	Flexeril
Dantrolene	Dantrium
Diazepam	Valium
Dronabinol	Marinol, Syndros
Estazolam	ProSom
Eszopiclone	Lunesta
Gabapentin	Gralise, Horizant,
Gubupentin	Neurontin
Lorazepam	Ativan
Metaxalone	Metaxall, Skelaxin
Methocarbamol	Robaxin
Orphenadrine	Norflex
Oxazepam	Serax
Pentobarbital	Nembutal
Phenobarbital	Luminal, Phenobarb
Pregabalin	Lyrica
Temazepam	Restoril
Tetrahydrocannabinol	Medical Marijuana
Tizanidine	Zanaflex
Triazolam	Halcion
Zaleplon	Sonata
Zolpidem	Ambien

Relevant Literature for Dental Providers

New Persistent Opioid Use – Dental One Page Infographic

This infographic provides a quick overview of current evidence relevant to dental providers on new persistent opioid use, unused prescription opioids and alternative options for pain control.






Available for download at: https://michigan-open.org/wp-content/uploads/2020/06/Dental-one_pager.pdf

4 Reasons Why (Dental)

This provider reference, created for health care professionals, uses recently published data to compel prescribers to optimize their opioid prescribing practice.





Available for download at: https://michigan-open.org/wp-content/uploads/2020/09/FINAL-4-Reasons Dental-09.08.2020.pdf

Community Referrals and Resources for Substance Use Disorder

The table below includes information for persons seeking treatment facilities and resources in Connecticut for substance use disorders.

Table 1. Community Referrals and Resources for Substance Use Disorder in Connecticut

Organization	Title		
ABH	Behavioral Health Recovery Program		
СТ ВНР	Connecticut Behavioral Health Partnership		
CT DCF	CT DCF Substance Use Services		
CT DCF	CT Connection Brochure (Resources for Teens)		
DMHAS	DMHAS Programs and Services – How to Find Services in Your Area		
DMHAS	Substance Use Disorder Treatment Resource Guide		
SAMHSA	Behavioral Health Treatment Service Locator		
United Way	2-11 of Connecticut		
Advanced Behavioral Health, Inc.			
CT BHP: Connecticut Behavioral Health Partnership			
CT DCF: Connecticut Department of Children and Families			
DMHAS: Department of Mental Health and Addiction Services			
SAMHSA: Substance Abuse and Mental Health Services Administration			

Board Certified Specialists of Orofacial Pain and TMD in Connecticut

The American Board of Orofacial Pain maintains an <u>Orofacial Pain Diplomate Directory</u> that lists board certified diplomates across the country that have trained and specialized in Orofacial Pain. As of August 2021, there are 270 credentialed Orofacial Pain diplomates in the United States; 3 of which practice in Connecticut and are listed alphabetically in the table below.

Table 2. Board Certified Specialists of Orofacial Pain and TMD in Connecticut

Diplomat Name	Address	Contact	University / Hospital Affiliation
Brijesh P. Chandwani	493 Westport Ave, Westport, CT 06851	203-842-8658	St. Barnabas Hospital, Bronx NYU Winthrop Tufts University
Seema Kurup	University of Connecticut Health Center, School of Dental Medicine 263 Farmington Ave Farmington, CT 06030	860-679-2852 kurup@uchc.edu	University of Connecticut Health Center
Bruce R. Sofferman	100 Bridgeport Ave Shelton, CT 06484	203-712-7727	

Orofacial Pain Consult Request Template

This Oral and Facial Pain Consult Request Form was developed to support dental practitioners with an asynchronous e-consult service by UConn Dental Faculty. The intention of this service is to provide support to clinicians treating cases that have not responded following use of established guidelines.

Oral and Facial Pain Consult Request [Provider to Provider]
Please send completed form via secure email to oralpainconsult@uchc.edu
Date:
Requesting Provider Name: Patient Name:
Organization/Practice: Patient DOB:
Provider Phone #:
Provider Secure Email:
1. Provide the primary reason/clinical question for the consult:
2. What are your expected outcome(s) following the completion of the consult? [check all that apply]
Devising a differential/definitive diagnosis
Recommendations for management/treatment
Recommendations for pharmacological modalities
Recommendations for non-pharmacological modalities
Recommendations for co-management with other health care professionals
Other (specify)
3. Background patient information necessary for the consult. Please include the following attachments with the consult request:
Labs and imaging pertaining to the consult
Current and past medication list
Current and past treatments
Relevant medical history
This form is for provider to provider communication and is not to be provided to the patient. This pilot consult service will be available through 8/31/21

CT State Legislation Related to Opioid Prescribing

Table 3. CT State Legislation Related to Opioid Prescribing

♦ Person's prescribed opioids for pain for 12 weeks or more must have documentation in their	
medical record by their provider in the form of an agreement or plan that includes risks, the need for urine drug screening, what would cause the prescription to be discontinued, and options for treating pain other than opioids.	
CT Public Act 17-131: An Act Preventing Opioid Diversion and Abuse	2017
 Limits opioid prescribing for minors to a 5 day supply of medications. 	
◆ Requires education for adult or minor patients that are prescribed an opioid drug regarding the risks associated with such opioid drug including but not limited to the risks of addiction and overdose associated with opioid drugs and the danger of taking opioid drugs with alcohol, benzodiazepines and other central nervous system depressants, and the reason the prescription is necessary, and if applicable with the custodial parent, guardian or other person having legal custody of the minor if such parent, guardian or other person is present at the time of issuance of the prescription.	
 Requires electronic prescribing of controlled substances. 	
CT Public Act 45, 42; An Act Concerning Original and Act Concerning Original Act Concerning Origina Act Concerning Original Act Concerning Origina Act Concerning Origina Act Concerni	2016
<u>CT Public Act 16-43: An Act Concerning Opioids and Access to Overdose Reversal Drugs</u> ◆ This law set a 7-day limit on opioid prescribing, but left room for exceptions which must be	2016
documented in the patient's medical record by the prescriber.	
 Practitioner's authorized agent, licensed or unlicensed, may register for their own CPMRS user account. 	
♦ Whenever a prescribing practitioner prescribes greater than a 72-hour supply of any <i>Schedule V</i> controlled substance for the treatment of any patient, such prescriber, or such prescriber's authorized agent, shall review, not less than annually, the patient's records in the CPMRS.	
CT Public Act 15-198: An Act Concerning Substance Abuse and Opioid Overdose Prevention	2015
 This legislation requires prescribers to check the CT Prescription Monitoring and Reporting System (CPMRS) if they want to prescribe more than a 72-hour supply of any controlled substance (including opioids). 	
CT Public Act 13-172: An Act Concerning the Electronic Prescription Drug Monitoring Program	2013
 All prescribers in possession of a Connecticut Controlled Substance Registration issued by the State of Connecticut, Department of Consumer Protection, will be required to register as a user with the Connecticut Prescription Monitoring and Reporting System (CPMRS) at https://connecticut.pmpaware.net. 	
 Any prescribers who dispense controlled substances from their practice or facility, etc., will be required to upload dispensing information into the CPMRS Data Collection website at https://pmpclearinghouse.net. 	

Opioid Related Guidelines and Recommendations Relevant to Dentists

Table 4. Opioid Related Guidelines and Recommendations Relevant to Dentists

Organization	Title	Year
Commonwealth of Pennsylvania	Prescribing Guidelines for Pennsylvania: Opioids in the Dental Practice	2019
American Dental Association	ADA Policy on Opioid Prescribing	2018
CORE (Center for Opioid Research and Education) at Johns Hopkins University	Dental Opioid Guidelines	2018
Bree Collaborative/Washington State Agency Medical Directors' Group	Dental Guidelines on Prescribing Opioids for Acute Pain Management	2017
New Jersey Dental Association	Resources for Safe Prescribing of Opioids and Non-Opiate Alternatives	2017
American Dental Association	ADA Statement on the Use of Opioids in the Treatment of Dental Pain	2016
Centers for Disease Control and Prevention	CDC Guidelines for Prescribing Opioids for Chronic Pain – United States, 2016	2016
Compendium of Education in Dentistry	Prescribing Recommendations for the Treatment of Acute Pain in Dentistry	2011

Appendices

Appendix I: Voluntary NonOpioid Directive Fact Sheet

Appendix II: Opioid Onset of Action

Appendix III: Morphine Milligram Equivalent (MME) Conversion Factors

Appendix IV: CPMRS Registration Policy and Procedures Manual

Appendix V: Ohio State Board of Pharmacy. Media Release: Dentist Enters Plea for Misuse of Ohio Prescription Monitoring System; October 8, 2013.



Voluntary NonOpioid Directive

Office of Injury Prevention • July 2018

Use of the Form under the Act

A "voluntary nonopioid directive form" (the "Form"), as established under and defined in section 4 of Public Act 17-131, an act Preventing Opioid Diversion and Abuse (the "Act"), available at:

https://www.cga.ct.gov/2017/ACT/pa/2017PA-00131-R00HB-07052-PA.htm enables an individual to voluntarily request that prescribing practitioners not prescribe opioid drugs and not issue a medication order for opioid drugs for such individual. This form is also known as an "opioid opt-out form."

A person who does not wish to be issued a prescription or medication order for an opioid drug may file this Form with a prescribing practitioner. Upon receipt of the Form from the patient, a prescribing practitioner shall document receipt of the Form in the patient's medical record. The patient and the patient's duly authorized guardian or health care proxy or representative may revoke the directive contained in said Form, orally or in writing, for any reason, at any time.

CT DPH encourages patients to complete the Form in consultation with their primary care providers or substance use disorder (SUD) treatment providers; however, such consultation is not required for the Form to be valid.

Liability under the Act

<u>Pharmacists:</u> An electronically transmitted prescription to a pharmacy shall be presumed to be valid. A pharmacist shall not be held in violation of the Act for dispensing a controlled substance in contradiction to a person's Form.

<u>Prescribing Practitioners:</u> A prescribing practitioner who willfully fails to comply with a patient's voluntary nonopioid directive form may be subject to disciplinary action pursuant to section 19a-17 of the general statutes. No prescribing practitioner acting with reasonable care shall be liable for damages in a civil action, subject to criminal prosecution or deemed to have violated the standard of care for such prescribing practitioner's profession for refusing to issue a prescription or medication order for an opioid pursuant to a person's Form.

Emergencies: No emergency department prescribing practitioner acting with reasonable care as the patient's practitioner or as the medical control officer for emergency medical services personnel, shall be liable for damages in a civil action, subject to criminal prosecution or deemed to have violated the standard of care for a prescribing practitioner's profession for issuing a prescription for or administering a controlled substance containing an opioid to a person who has a voluntary nonopioid directive form, when, in such prescribing practitioner's professional medical judgment, a controlled substance containing an opioid is necessary and such prescribing practitioner had no knowledge of the patient's voluntary nonopioid directive form at the time of issuance or administration.

<u>Guardian or Health Care Proxy or Representative</u>: No person acting in good faith as a patient's duly authorized guardian or health care proxy or representative shall be liable for damages in a civil action or subject to criminal prosecution for revoking or overriding a voluntary nonopioid directive form.

Resources

- CDC Guideline Information for Prescribers: http://www.cdc.gov/drugoverdose/prescribing/providers.html
- CDC Guideline for Prescribing Opioids for Chronic Pain: https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm

Connecticut Department of Public Health
410 Capitol Avenue, Hartford, CT 06134
Office of Injury Prevention • 860-509-8251 • www.ct.gov/dph/injuryprevention

Available for download at: https://business.ct.gov/-/media/DPH/fact sheet VNOD-quidance-72018.pdf

Appendix II: Opioid Onset of Action


Opioid (oral)	Onset of Action (minutes)	Duration of Action (hours)	Peak Effect (hours)
Codeine	30-60	4-6	0.5-1
Hydrocodone	15-60	4-6	0.5-1
Hydromorphone	15-30	4-6	1.5-2
Methadone	30-60	6-8	1-2
Morphine (IR)	30-60	3-6	1
Oxycodone (IR)	10-45	4-6	1-2
Oxymorphone	5-15	3-6	0.5-1
Tramadol (IR)	60	3-6	2-3

Calculating morphine milligram equivalents (MME)

OPIOID (doses in mg/day except where noted)	CONVERSION FACTOR	
Codeine	0.15	
Fentanyl transdermal (in mcg/hr)	2.4	
Hydrocodone	1	
Hydromorphone	4	
Methadone		
1-20 mg/day	4	
21-40 mg/day	8	
41-60 mg/day	10	
≥ 61-80 mg/day	12	
Morphine	1	
Oxycodone	1.5	
Oxymorphone	3	

These dose conversions are estimated and cannot account for all individual differences in genetics and pharmacokinetics.

For CT providers, read the following:



Appendix V: Ohio State Board of Pharmacy. Media Release: Dentist Enters Plea for Misuse of Ohio Prescription Monitoring System; October 8, 2013.

Practitioners can only search PMP databases for active patients of record: searching the databases for individuals who are not active patients constitutes a breach of privacy with results in serious legal consequences that potentially jeopardize, among other things, professional licensure.



OHIO STATE BOARD OF PHARMACY

77 South High Street, Room 1702; Columbus, OH 43215-6126

-Equal Opportunity Employer and Service Provider

Contact: Jesse L. Wimberly, PIO

Phone: 937-603-4111 Fax: 937-832-3110

October 8, 2013

Media Release

Dentist Enters Plea for Misuse of Ohio Prescription Monitoring System

Solon, Ohio (Cuyahoga County) - On October 7, 2013, Ohio State Board of Pharmacy Executive Director Kyle Parker, announced that Dr. Fred S. Glick, 55, has entered into a plea agreement with the Cuyahoga County Prosecutor's Office for his misuse of the Ohio Automated Rx Reporting System (O.A.R.R.S.).

The Ohio State Board of Pharmacy initiated an investigation in January 2013, after receiving a complaint that Dr. Glick allegedly ran an O.A.R.R.S. report inappropriately. As a result of the investigation, it was discovered that Dr. Glick accessed the O.A.R.R.S. database twenty one times and illegally obtained prescription data from the time period of February 2012 through December 2012. At the time he accessed the database, the person was not a patient of Dr. Glick. Therefore, he had no legal authority or reason to access the information.

A Cuyahoga County Grand Jury indicted Dr. Glick on April 16, 2013, on twenty-one felony counts of the misuse of the O.A.R.R.S. database. Prior to Dr. Glick's trial scheduled on October 7, 2013, he entered a plea of guilty to only one felony count, and was subsequently sentenced to six months probation and ordered to pay a \$2,500.00 fine.

"This is a great accomplishment, as this is the first conviction in Ohio for the improper use of O.A.R.R.S," said Ohio State Board of Pharmacy Spokesman, Jesse Wimberly.

The Ohio State Board of Pharmacy is the governing agency of the Ohio Automated Rx Reporting System, which is a prescription monitoring program established in 2006 as a tool to assist healthcare professionals and law enforcement agencies to quickly identify drug seeking behaviors and patterns of improper prescribing by physicians. Misuse of the O.A.R.R.S. data is a criminal offense under Ohio Revised Code 4729.86.

The Ohio State Board would like to thank Cuyahoga County Prosecutor Timothy McGinty, and Cuyahoga County Assistant Prosecutors Denise Salerno and Nicholas Reif, for their support with this investigation.